Frequency: once daily
Sponsors
Department of Neurology, Xuanwu Hospital, Intas Pharmaceuticals Ltd, Intas Pharmaceuticals Limited, Professor Anders Perner, Department of Pediatrics
Conditions
Cerebellar AtaxiaHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsHealth Condition 1: F209- Schizophrenia, unspecifiedHealth Condition 1: J958- Other intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classifiedHealth Condition 1: M068- Other specified rheumatoid arthritis
Phase 2
Phase 3
A Study of Tacrolimus Tablets in Adult Patients with autoimmune disorder that primarily affects joints
Active, not recruitingCTRI/2019/05/018873
Target: 364Updated: 2023-05-29
Higher vs. Lower Doses of Steroids in Patients with COVID-19
Active, not recruitingCTRI/2020/10/028731
Target: 1500Updated: 2021-11-24
A study to determine whether administering an inhaled antibiotic can prevent pneumonia in children who are on a ventilator
Active, not recruitingCTRI/2024/11/076717
Target: 184Updated: 2024-12-09
Unknown Phase
A STUDY OF CLOZAPINE EXTENDED RELEASE CAPSULE 25 MG WITH CLOZAPINE EXTENDED RELEASE CAPSULE 200 MG IN ADULT SCHIZOPHRENIC PATIENTS UNDER FASTING CONDITIONS.
Active, not recruitingCTRI/2019/10/021798
Target: 82Updated: 2021-11-24
A Clinical Study on the Safety and Efficacy of Novel tTIS Technology Targeting the Cerebellum in the Treatment of Patients with Cerebellar Ataxia
Active, not recruitingChiCTR2500110011
Start: 2025-10-09Updated: 2025-10-06